Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Breast Neoplasms 84Neoplasm Metastasis 59Prostatic Neoplasms 57Leukemia, Myeloid, Acute 57Melanoma 49Multiple Myeloma 47Colorectal Neoplasms 44Lung Neoplasms 43Pancreatic Neoplasms 39Carcinoma, Non-Small-Cell Lung 38Lymphoma 37Neoplasms 30Myelodysplastic Syndromes 30Leukemia, Lymphocytic, Chronic, B-Cell 30Squamous Cell Carcinoma of Head and Neck 28Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 24Ovarian Neoplasms 24Burkitt Lymphoma 21Rectal Neoplasms 20Lymphoma, Follicular 19Colonic Neoplasms 19Uterine Cervical Neoplasms 18Stomach Neoplasms 18Sarcoma 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Lymphoma, Mantle-Cell 17Glioma 17Head and Neck Neoplasms 16

Interventions

Peripheral Blood Stem Cell Transplantation 26Rituximab 20Cyclophosphamide 18fludarabine phosphate 17Mycophenolic Acid 16Tacrolimus 14Cyclosporine 14Whole-Body Irradiation 12Filgrastim 11Therapeutics 10Psychiatric Rehabilitation 10Flow Cytometry 10Etoposide 10Radiotherapy 8Polymerase Chain Reaction 8Methotrexate 8Busulfan 8Methylprednisolone 7Antilymphocyte Serum 7Cladribine 6immunotoxin HA22 5Lenalidomide 5obinutuzumab 4Vorinostat 4Vemurafenib 4Ondansetron 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × Biopsy × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06311227 2026-05-13

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡